Product Description: Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.
Applications: Cancer-Kinase/protease
Formula: C29H44N8O3
Citations: Acta Biomater. 2024 Sep 3:S1742-7061(24)00505-1./Biomed Pharmacother. 2023 Jun 29;165:115066./Biomed Pharmacother. 2024 Oct 28:180:117603./Blood Cancer J. 2022 Jan 11;12(1):5./Blood Cancer J. 2025 Mar 15;15(1):40./Cancer Cell Int. 2020 Jun 17;20:250./Cancer Cell. 2024 Nov 11;42(11):1955-1969.e7./Cancer Discov. 2023 Apr 3;CD-22-0411./Cancer Lett. 2024 May 3:216933./Cancer Res Commun. 2024 Jan 29./Cancers. 2020 Aug 19;12(9):2341./Cancers. 2020 Jun 14;12(6):1574./Cell Biol Toxicol. 2024 Nov 28;40(1):105./Cell Rep Med. 2024 Jul 16;5(7):101645./Cell Rep. 2024 Sep 25:114774./Comput Biol Med. 2023 Dec 21, 107889./Department of Pharmacology & Toxicology. 2020 Jul./Front Pharmacol. 2021 Mar 8;12:644342./Haematologica. 2018 Nov;103(11):1862-1872./J Control Release. 2024 Feb 15:367:821-836./J Oncol. 21 Sep 2021./Mol Cancer Res. 2021 Oct 11./Mol Pharmacol. April 5, 2022./Mol Syst Biol. 2023 Dec 18./Nat Cancer. 2024 May 30./Polymers. 2024 Jan 12, 16(2), 225./Research Square Preprint. 2023 Dec 6./Sci Adv. 2022 Sep 16;8(37):eabp9005./Sci Rep. 2021 Mar 11;11(1):5715./Science. 2017 Dec 1;358(6367):eaan4368./Separations. 2023 Apr 25, 10(5), 278./Target Oncol. 2022 Oct 6./Blood Cancer Discov. 2022 Mar 4;bloodcandisc.0163.2021./Eur J Med Chem. 2022 Jul 5;237:114356.
References: [1]ASP2215, a novel FLT3/AXL inhibitor: Preclinical evaluation in acute myeloid leukemia (AML). 2014 ASCO Annual Meeting./[2]Mori M, et al. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest New Drugs. 2017 Oct;35(5):556-565.
CAS Number: 1254053-43-4
Molecular Weight: 552.71
Compound Purity: 99.84
Research Area: Cancer
Solubility: DMSO : 2 mg/mL (ultrasonic)/Ethanol : 100 mg/mL (ultrasonic;adjust pH to 2 with HCl)
Target: FLT3;TAM Receptor
English
Deutsch
